These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 22640790)

  • 21. [Expression and gene mutation of phospho-platelet derived growth factor receptor alpha and C-kit in gastrointestinal and extra-gastrointestinal stromal tumors].
    Tang M; Li DQ
    Zhonghua Wei Chang Wai Ke Za Zhi; 2008 Jan; 11(1):80-3. PubMed ID: 18197502
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate.
    Wardelmann E; Merkelbach-Bruse S; Pauls K; Thomas N; Schildhaus HU; Heinicke T; Speidel N; Pietsch T; Buettner R; Pink D; Reichardt P; Hohenberger P
    Clin Cancer Res; 2006 Mar; 12(6):1743-9. PubMed ID: 16551858
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gastrointestinal stromal tumors: a 7-year experience from a tertiary care hospital.
    Lakshmi VA; Chacko RT; Kurian S
    Indian J Pathol Microbiol; 2010; 53(4):628-33. PubMed ID: 21045382
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Therapeutic consequences from molecular biology for gastrointestinal stromal tumor patients affected by neurofibromatosis type 1.
    Mussi C; Schildhaus HU; Gronchi A; Wardelmann E; Hohenberger P
    Clin Cancer Res; 2008 Jul; 14(14):4550-5. PubMed ID: 18628470
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A novel germline KIT mutation (p.L576P) in a family presenting with juvenile onset of multiple gastrointestinal stromal tumors, skin hyperpigmentations, and esophageal stenosis.
    Neuhann TM; Mansmann V; Merkelbach-Bruse S; Klink B; Hellinger A; Höffkes HG; Wardelmann E; Schildhaus HU; Tinschert S
    Am J Surg Pathol; 2013 Jun; 37(6):898-905. PubMed ID: 23598963
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Effect of c-kit mutation on the prognosis of gastrointestinal stromal tumors: a meta-analysis].
    Zhao WY; Cao H; Zhang Y; Shen ZY; Wu ZY
    Zhonghua Wai Ke Za Zhi; 2009 Jun; 47(11):857-62. PubMed ID: 19961019
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [A case of metastatic gastrointestinal stromal tumor developing a resistance to STI571 (imatinib mesylate)].
    Miyake M; Takeda Y; Hasuike Y; Kashiwazaki M; Mishima H; Ikenaga M; Mano M; Takada Y; Hirota S; Tsujinaka T
    Gan To Kagaku Ryoho; 2004 Oct; 31(11):1791-4. PubMed ID: 15553717
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rectal gastrointestinal stromal tumors associated with a novel germline KIT mutation.
    Woźniak A; Rutkowski P; Sciot R; Ruka W; Michej W; Debiec-Rychter M
    Int J Cancer; 2008 May; 122(9):2160-4. PubMed ID: 18183595
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Study on the mechanism of imatinib-induced resistance in gastrointestinal stromal tumors].
    Zhou Y; Hou YY; Tan YS; Lu SH; Hou J; Liu JL; Qin J; Shen KT; Sun YH
    Zhonghua Zhong Liu Za Zhi; 2009 Aug; 31(8):597-601. PubMed ID: 20021947
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [GIST: a clinical case as a model of surgical and pharmacological therapy of solid tumours].
    D'Amato A; Pezzoli F; Caterino S; Cavallini M; Balducci G; Bocchetti T; Ziparo V
    Chir Ital; 2005; 57(4):509-14. PubMed ID: 16060192
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gastrointestinal stromal tumors presenting as omental masses--a clinicopathologic analysis of 95 cases.
    Miettinen M; Sobin LH; Lasota J
    Am J Surg Pathol; 2009 Sep; 33(9):1267-75. PubMed ID: 19440146
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Imatinib in the management of multiple gastrointestinal stromal tumors associated with a germline KIT K642E mutation.
    Graham J; Debiec-Rychter M; Corless CL; Reid R; Davidson R; White JD
    Arch Pathol Lab Med; 2007 Sep; 131(9):1393-6. PubMed ID: 17824795
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A mouse model of a human multiple GIST family with KIT-Asp820Tyr mutation generated by a knock-in strategy.
    Nakai N; Ishikawa T; Nishitani A; Liu NN; Shincho M; Hao H; Isozaki K; Kanda T; Nishida T; Fujimoto J; Hirota S
    J Pathol; 2008 Feb; 214(3):302-11. PubMed ID: 18098338
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Minute gastric sclerosing stromal tumors (GIST tumorlets) are common in adults and frequently show c-KIT mutations.
    Agaimy A; Wünsch PH; Hofstaedter F; Blaszyk H; Rümmele P; Gaumann A; Dietmaier W; Hartmann A
    Am J Surg Pathol; 2007 Jan; 31(1):113-20. PubMed ID: 17197927
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Different factors are responsible for predicting relapses after primary tumors resection and for imatinib treatment outcomes in gastrointestinal stromal tumors.
    Rutkowski P; Debiec-Rychter M; Nowecki ZI; Wozniak A; Michej W; Limon J; Siedlecki JA; Jerzak Vel Dobosz A; Grzesiakowska U; Nasierowska-Guttmejer A; Sygut J; Nyckowski P; Krawczyk M; Ruka W
    Med Sci Monit; 2007 Nov; 13(11):CR515-522. PubMed ID: 17968300
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The GIST of a tumor's transformation.
    Nelson B
    Cancer Cytopathol; 2010 Jun; 118(3):114. PubMed ID: 20544705
    [No Abstract]   [Full Text] [Related]  

  • 37. [Morphological characteristics and prognostic criteria for gastrointestinal stromal tumors].
    Tsyganova IV; Anurova OA; Mazurenko NN
    Arkh Patol; 2011; 73(6):37-42. PubMed ID: 22379899
    [TBL] [Abstract][Full Text] [Related]  

  • 38. c-Kit/PDGFRA gene status alterations possibly related to primary imatinib resistance in gastrointestinal stromal tumors.
    Miselli FC; Casieri P; Negri T; Orsenigo M; Lagonigro MS; Gronchi A; Fiore M; Casali PG; Bertulli R; Carbone A; Pierotti MA; Tamborini E; Pilotti S
    Clin Cancer Res; 2007 Apr; 13(8):2369-77. PubMed ID: 17438095
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A prospective, multicenter, phase 2 study of imatinib mesylate in korean patients with metastatic or unresectable gastrointestinal stromal tumor.
    Ryu MH; Kang WK; Bang YJ; Lee KH; Shin DB; Ryoo BY; Roh JK; Kang JH; Lee H; Kim TW; Chang HM; Park JO; Park YS; Kim TY; Kim MK; Lee WK; Kang HJ; Kang YK
    Oncology; 2009; 76(5):326-32. PubMed ID: 19307738
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Treatment of patients with gastrointestinal stromal tumour with imatinib mesylate].
    Haugland HK; Jebsen NL; Mannelqvist M; Skar R; Eide J; Øvrebø K; Horn A; Jensen DK; Monge OR; Lilleng PK
    Tidsskr Nor Laegeforen; 2005 Apr; 125(7):868-72. PubMed ID: 15815732
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.